For the week of March 20 to March 24, 2017

Monday Tuesday Wednesday Thursday Friday

Monday's Reports


These business pages will run from Monday thru Friday. Different reports each day starting Monday and adding webpages throughout the week. Our Business Reports will feature local California companies.

 

Epson Disrupts High Performance Corporate Printer Market with New WorkForce Color A3 Multifunction Printers

LONG BEACH, CA...March 20, 2017 - Epson America, Inc., a leading provider of superior performing printing solutions, today debuted its first corporate high-speed inkjet line head printer – the WorkForce® Enterprise WF-C20590 A3 multifunction printer – designed for SMB and corporate workgroups. Powered by PrecisionCore® Line Head Technology, the new
WF-C20590 offers breakthrough speed, up to 100 ISO ppm†, optimized for workgroup productivity and versatility. In addition, Epson today introduced the WorkForce Pro WF-C869R A3 multifunction printer. Leveraging the Epson Replaceable Ink Pack System, the
WF-C869R offers lowest color printing in its class1.

"By leveraging Epson's high-speed production inkjet technology, we were able to solve a long time-challenge for SMB and large workgroups: making color printing in the office accessible to all, at an affordable cost," said Mark Mathews, commercial vice president of marketing, Epson America, Inc. "Delivering 100 pages per minute†, the WorkForce Enterprise WF-C20590 is the first in a new class of Epson printers that integrate PrecisionCore Line Head Technology to unleash unrestricted and cost-effective color printing in the office."

"With the WorkForce Enterprise WF-C20590, Epson is bringing high-speed innovation into the multi-billion dollar office printing industry, creating growth opportunities for resellers to expand the color printing market," said Ray Looney, vice president of sales, Impression Solutions, Inc., a national value-added distributor of imaging technology and office equipment. "The WF-C20590 and WF-C869R are exciting for us because they provide the ability to offer cost-effective color printing with the reliability our customers demand, which opens new markets for us."

WorkForce Enterprise WF-C20590 A3 Multifunction Printer – delivers high-quality output and breakthrough speed of up to 100 ISO ppm†,the fastest in its class2. Epson's first PrecisionCore line head multifunction color printer is a powerful workhorse, while utilizing 50 percent less power than color lasers2 and operating on a standard 110-volt outlet. For a faster workflow, the WF-C20590 offers a standard 2,350-page paper capacity3, an optional 3,000 sheet high input capacity unit, and an optional finisher for collating and stapling. Its high-yield large capacity ink cartridges deliver up to 100,000 black4 / 50,000 color ISO pages* before replacement. The WF-C20590 features Epson Open Platform for seamless integration with web-based enterprise applications such as PaperCut MF and other workflows, and is fully MPS compliant.

WorkForce Pro WF-C869R A3 Multifunction Printer – offers the lowest color printing costs in its class1. Its Replaceable Ink Pack System delivers up to 84,000 ISO pages before changing the ink packs5, which means fewer interventions and less hassle compared to previous models. The printer offers professional-quality prints at 24 ISO ppm (black/color)†, and scans up to 25 images per minute6. With 13"x19" printing, a 1,830-sheet total paper capacity7, convenient auto duplexing, and workflow integration with Epson Open Platform, the WF-C869R provides versatility for busy workgroups.

Availability
The Epson WorkForce Enterprise WF-C20590 will be available summer 2017 through participating BTA resellers. The WorkForce Pro WF-C869R will be available through authorized BTA resellers starting spring 2017. For more information and availability, please visit www.epson.com. For further information, resellers can contact Lauren Lung, North America Sales Manager Enterprise, at Lauren.Lung@ea.epson.com.

About Epson
Epson is a global technology leader dedicated to connecting people, things and information with its original efficient, compact and precision technologies. With a lineup that ranges from inkjet printers and digital printing systems to 3LCD projectors, smart glasses, sensing systems and industrial robots, the company is focused on driving innovations and exceeding customer expectations in inkjet, visual communications, wearables and robotics.

 

 

Cesca CLI Feasibility Study Published in Peer-Reviewed Journal

RANCHO CORDOVA, CA...March 20, 2017 - Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the publication in a peer reviewed journal of data from its Critical Limb Ischemia (CLI) feasibility study utilizing the Company's innovative point-of-care technology. The report was published in the "Stem Cells International" and is available online at https://www.hindawi.com/journals/sci/2017/4137626/ref/.

Results from the seventeen patient clinical study titled, "Safety and Effectiveness of Bone Marrow Cell Concentrate in the Treatment of Chronic Critical Limb Ischemia Utilizing a Rapid Point-of-Care System", (the "Study") were obtained using Cesca's automated point-of-care technology. The single treatment procedure was performed at the patient's bedside and took less than 60 minutes. The Study results showed significant improvement in wound healing, rest pain and six-minute walking distance, along with significant reduction in intermittent claudication pain following the treatment.

Dr. Venkatesh Ponemone, Study Director and Executive Director of TotipotentRX, a Cesca subsidiary and the corresponding author of the article commented, "We are targeting difficult to treat or life threatening conditions such as CLI with our autologous, cell-based therapies. We believe our innovative point-of-care cell processing systems, such as those used in the Study, can play an important role in optimizing the quality and quantity of target cells used to improve patient outcomes."

Dr. Xiaochun "Chris" Xu, Cesca's Interim CEO added, "We are pleased that the Study was recognized and published in a peer reviewed journal. The encouraging data highlights Cesca's capability to develop effective automated cellular processing systems. We welcome strategic partners to help us further refine their use in larger clinical settings."

About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics. These include:

The SurgWerks™ System (in development) - a proprietary system comprised of the SurgWerks Processing Platform, including devices and analytics, and indication-specific SurgWerks Procedure Kits for use in regenerative stem cell therapy at the point-of-care for vascular and orthopedic diseases.

The CellWerks™ System (in development) - a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood.

The AXP® System - a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood.

The MXP® System - a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow.

The BioArchive® System - an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use.
Manual bag sets for use in the processing and cryogenic storage of cord blood.

 

 

Nozomi Networks Delivers First End-to-End Platform for Improved ICS Cybersecurity and Operational Reliability

MENLO PARK, CA...March 20, 2017 - Nozomi Networks Inc., the pioneer in real-time cybersecurity and operational visibility for industrial control systems (ICS), today realized another industry milestone with its latest release of SCADAguardian. The trusted solution for cybersecurity risk detection is now the industry's first solution to support both operational visibility and ICS cybersecurity with new modules for Asset Management and Vulnerability Assessment. It also introduces innovative Dynamic Learning for configuration-free deployments. This gives energy utilities, oil and gas operators and manufacturers the industry's only single solution to comprehensively monitor control networks for cybersecurity and operational anomalies.

"At Vermont Electric our mission is to provide safe, affordable, and reliable energy services to our members," said Kris Smith, SCADA and Operations Engineering Manager. "In order to do that, we need both operational visibility and cybersecurity protection for our critical operations systems. We're working with Nozomi Networks because their deep industrial cybersecurity expertise is embedded in one clean, comprehensive solution, from network modeling to process anomaly and intrusion detection. With Nozomi Networks we're investing in the future reliability and efficiency of our operations."

Click to Tweet: With @NozomiNetworks we're investing in the future reliability and efficiency of our operations. - Kris Smith, Vermont Electric http://bit.ly/2mAfytD

"Our customers love the way SCADAguardian uses AI and machine learning to deliver effective ICS cybersecurity and anomaly detection," said Nozomi Networks Co-founder and Chief Product Officer, Andrea Carcano. "But, similar to the needs at Vermont Electric, many were asking if we could leverage that functionality to help streamline operational tasks. That's why we are offering new modules that simplify operations and ultimately improve operational visibility and monitoring for stronger cyber resilience and ICS reliability."

NEW Comprehensive Asset Management
For industrial operators, tracking assets and knowing their configuration and firmware versions, as well as other attributes, is often a lengthy manual process that is prone to human error and hard to keep up-to-date. SCADAguardian 17.0 automates asset tracking, keeps information current, and makes it easy to visualize, find and drill down on asset information such as software and hardware versions. Alerts, consolidated into context-aware incidents, notify operators of changes that may indicate a cybersecurity or operational incident.

NEW Vulnerability Assessment
SCADAguardian makes it possible for operators to stay on top of device vulnerabilities, updates and patch requirements. By constantly analyzing industrial network assets against a state-of-the-art repository of ICS vulnerabilities, SCADAguardian saves time and improves cyber resiliency. A dedicated view of all vulnerabilities and their severity facilitates fast remediation.

NEW Dynamic Learning
When it comes to comprehensive ICS modeling supported by AI and machine learning, SCADAguardian is well known for its automated learning phase in which it builds an accurate behavioral model of what every industrial device should be doing at every phase in the process. Until now, operators were required to perform a configuration step in order to switch the system from learning to protection mode. Now learning granularity has increased so that learning, and the switch to protection now happen automatically per node and per network segment. Stable network nodes and segments become protected automatically. Operators are not overwhelmed with alerts due to the premature closing of learning mode.

These latest capabilities join a robust set of security monitoring modules in SCADAguardian to deliver the industry's first and only single solution for both effective operational visibility and the strongest possible cybersecurity threat detection. Visit www.nozominetworks.com to learn more about the newest release of SCADAguardian.

Supporting Quotes

Ken Hans, Vice President, Trellis Energy
"This latest release of SCADAguardian satisfies a growing need among oil and gas producers looking for effective ways to address cyber security while improving operational efficiency. By combining advanced ICS Cybersecurity monitoring capabilities with new modules for asset management and vulnerability assessment, SCADAguardian can now solve for both. SCADAguardian not only eliminates exhaustive manual processes to inventory industrial assets and networks, but also provides a real-time view into potential industrial vulnerabilities and vastly improves cybersecurity threat detection and prevention for business-critical infrastructure."

John Maddison, SVP Products and Solutions, Fortinet
"With the increasingly hyperconnected nature of OT, ICS and SCADA systems, integrated cybersecurity is critical to be able to collect and correlate threat intelligence in real time, identify behavior anomalies, and automatically orchestrate responses. Nozomi Networks' latest release of SCADAguardian further bolsters its integration with the Fortinet Security Fabric to deliver the required level of security visibility and automation for evolving industrial control systems and critical infrastructure networks."


 

Opiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa

SANTA MONICA, CA...March 20, 2017 - Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that the Company has initiated a Phase 2 clinical trial evaluating its novel nasally-delivered opioid antagonist candidate, OPNT001, as a potential treatment for Bulimia Nervosa.

"Bulimia Nervosa is a serious and potentially life-threatening eating disorder for which new treatment options are desperately needed," said Janet Treasure OBE, PhD, FRCP, FRCPsych, Professor of Psychiatry at King's College London, and principal investigator of the study. "Compulsive bingeing has features in common with other addiction disorders, providing strong rationalization for the use of opioid antagonists to mitigate the frequency of these harmful behaviors. OPNT001 is absorbed rapidly, and allows for potential targeted dosing, which we believe could address the unique needs of patients suffering from this serious disorder."

"We continue to leverage our expertise in nasally-delivered opioid antagonists, which led to the successful development of NARCAN® Nasal Spray for opioid overdose, to address broader chronic addiction disorders with large and undertreated patient populations," said Roger Crystal, M.D., Chief Executive Officer of Opiant Pharmaceuticals. "The advancement of OPNT001 into Phase 2 development for Bulimia Nervosa was a key 2017 clinical goal for our Company as we continue to expand and advance our pipeline of promising addiction treatments. We look forward to data from this important study next year."

This Phase 2 randomized, double-blind, placebo-controlled study will enroll up to 80 patients in the U.K. who have been diagnosed with Bulimia Nervosa. The study is designed to evaluate OPNT001's safety and tolerability, as well as its impact on clinical outcomes, including changes in eating behavior. The Company expects to report topline data from this study in the first half of 2018.

About Bulimia Nervosa

Bulimia Nervosa is a serious and potentially life-threatening eating disorder affecting mainly females, and is characterized by binge eating followed by purging, fasting, and other strategies to prevent weight gain. It has a lifetime prevalence of 1-2%, and patients are at a heightened risk of other mental disorders including depression, anxiety and problems with drug and alcohol. The mainstay of treatment is psychotherapy using cognitive behavioral therapy, but this is associated with only moderate treatment success and high relapse rates. Fluoxetine is currently the only FDA approved medication to treat Bulimia Nervosa. However, the remission rate with fluoxetine, both alone and combined with psychotherapy, ranges from only 19-41%.

The wide variety of individual response to treatment, combined with moderate success of even the most effective treatment approaches, highlights a strong need to develop new and more effective treatments. Research suggests that treatments based on the addiction model of bingeing may be of benefit. Thus, many experts view binge eating as a form of addictive behavior to foods high in sugar, salt and fat. Furthermore, individuals with "food addiction" exhibit similar patterns of brain activation in response to both the anticipation and receipt of food. This pattern is similar to that observed in patients with drug and alcohol addiction/use disorders.

About OPNT-001

OPNT-001 is Opiant's proprietary nasal naloxone technology. The product is covered by three FDA Orange Book-listed patents. PET imaging and promising pharmacokinetic data, which demonstrate rapid absorption, render it uniquely suitable for targeted dosing.

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders. Over 45 million people in the U.S. have one of these disorders. The National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company's partner, Adapt Pharma Limited. For more information please visit: www.opiant.com.

 

 

AXT, Inc. Resumes Substrate Production at Its Beijing Manufacturing Facility

FREMONT, CA...March 20, 2017 - AXT, Inc. (NasdaqGS:AXTI), a leading manufacturer of compound semiconductor substrates, today announced that it has resumed wafer processing production of all substrate types, including indium phosphide (InP), gallium arsenide (GaAs) and germanium (Ge), at its manufacturing facility in Beijing, China, following an electrical fire on March 16, 2017.

As previously reported, the fire caused no damage to indium phosphide crystal growth or wafer production. In addition, the company's 6-inch gallium arsenide and germanium crystal growth furnaces were not damaged by the fire, and there is no damage to the electrical supply supporting these 6-inch crystal growth furnaces. The electrical power supply supporting 2-inch, 3-inch and 4-inch gallium arsenide and germanium crystal growth was damaged. The company's custom-designed furnaces enable it to rotate key furnace hardware between different growth diameters. The company plans to use some of the 6-inch furnace capacity for 2-inch, 3-inch and 4-inch diameter gallium arsenide and germanium crystal growth production.

In addition to rotating diameter sizes, the company has sufficient redundancy in furnaces and plans to move furnaces within the plant to an area designated for crystal growth expansion. Power can then be connected and the company can restore the smaller diameter crystals to full production. The company believes it can return to full production during the second quarter. Further, to meet immediate customer demand, staged inventory of smaller diameter crystalline ingots will be moved to wafer processing.

AXT's wafer processing production area, including its clean room, is housed in a facility across the street from the building in which the electrical short circuit fire occurred, and was not affected by this event. Further, as it previously announced, no structural damage occurred to the building in which the fire took place.

"I am thankful that no injuries occurred and that the damage to our facilities was considerably less than we initially believed," said Morris Young, chief executive officer. "Further, I am grateful to local authorities for their timely response and assistance. We remain convinced about our business opportunities and are deeply committed to supporting the requirements of our customers through this process."

About AXT, Inc.

AXT designs, develops, manufactures and distributes high-performance compound and single element semiconductor substrates comprising indium phosphide (InP), gallium arsenide (GaAs) and germanium (Ge) through its manufacturing facilities in Beijing, China. In addition, AXT maintains its sales, administration and customer service functions at its headquarters in Fremont, California. The company's substrate products can be used primarily in fiber optic communications, 3-D sensing, solar cell, lighting display applications and wireless communications. Its vertical gradient freeze (VGF) technique for manufacturing semiconductor substrates provides significant benefits over other methods and enabled AXT to become a leading manufacturer of such substrates. AXT has manufacturing facilities in China and, as part of its supply chain strategy, has partial ownership in ten companies in China producing raw materials. For more information, see AXT's website at http://www.axt.com.

 

Cytokinetics Announces Additional Results From COSMIC-HF Presented at ACC.17

SOUTH SAN FRANCISCO, CA...March 20, 2017 - Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, were presented by Tor Biering-Sørensen, MD, PhD, Postdoctoral Research Fellow, Division of Cardiology, Brigham & Women's Hospital and Harvard Medical School, in a Poster Session at the American College of Cardiology's 66th Annual Scientific Session (ACC.17) in Washington, D.C. The results presented showed that omecamtiv mecarbil improved myocardial deformation, a marker of myocardial function that has been related to outcomes. Omecamtiv mecarbil, a novel investigational cardiac myosin activator that increases cardiac contractility, is being developed by Amgen in collaboration with Cytokinetics for the potential treatment of heart failure.

"These results provide the first, direct echocardiographic evidence in humans that increases in the contractility of cardiac muscle underlie the improvements in overall cardiac function observed in COSMIC-HF," said Fady I. Malik, MD, PhD, Cytokinetics' Executive Vice President, Research and Development.

COSMIC-HF: Expansion Phase Design and Results

The expansion phase of COSMIC-HF evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of oral omecamtiv mecarbil in 448 patients with chronic heart failure and left ventricular systolic dysfunction. Patients were randomized 1:1:1 to receive either placebo or treatment with omecamtiv mecarbil dosed as 25 mg twice daily or 25 mg twice daily with dose escalation to 50 mg twice daily, depending on a plasma concentration of omecamtiv mecarbil after two weeks of treatment. The study met its primary pharmacokinetic objective and showed statistically significant improvements in all pre-specified secondary measures of cardiac function in the treatment group receiving pharmacokinetic-based (PK) dose titration.

In this analysis, measures of left ventricular (LV) myocardial deformation, including global circumferential strain (GCS) and mean global longitudinal strain (GLS), were compared at baseline and at 20 weeks of treatment in the placebo group, the 25 mg twice daily group, and the PK-guided dose titration group. At 20 weeks, both mean GLS and GCS improved in the 25 mg twice daily group (p=0.014, p=0.001, respectively), and showed a trend towards improvement in the PK-guided dose titration group (p=0.06, p=0.13, respectively). These results further support that omecamtiv mecarbil directly improves myocardial contractile function.

About Heart Failure

Heart failure is a grievous condition that affects more than 23 million people worldwide, about half of whom have reduced left ventricular function. It is the leading cause of hospitalization and readmission in people age 65 and older. Despite broad use of standard treatments and advances in care, the prognosis for patients with heart failure is poor. An estimated one in five people over the age of 40 are at risk of developing heart failure, and approximately 50 percent of people diagnosed with heart failure will die within five years of initial hospitalization.

About Omecamtiv Mecarbil

Omecamtiv mecarbil is a novel cardiac myosin activator. Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy into the mechanical force resulting in cardiac contraction. Cardiac myosin activators are thought to accelerate the rate-limiting step of the myosin enzymatic cycle and shift the enzymatic cycle in favor of the force-producing state. Preclinical research has shown that cardiac myosin activators increase contractility in the absence of changes in intracellular calcium in cardiac myocytes.

Omecamtiv mecarbil is being developed by Amgen in collaboration with Cytokinetics. Amgen holds an exclusive, worldwide license to omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization rights. Amgen has also entered an alliance with Servier for exclusive commercialization rights in Europe as well as the Commonwealth of Independent States, including Russia. Servier contributes funding for development and provides strategic support to the program.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal troponin activator (FSTA). Tirasemtiv is the subject of VITALITY-ALS, an international Phase 3 clinical trial in patients with ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. Cytokinetics is preparing for the potential commercialization of tirasemtiv in North America and Europe and has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. Cytokinetics is collaborating with Astellas to develop CK-2127107, a next-generation fast skeletal muscle activator. CK-2127107 is the subject of two ongoing Phase 2 clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of GALACTIC-HF, an international Phase 3 clinical trial in patients with heart failure. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Astellas holds an exclusive worldwide license to develop and commercialize CK-2127107. Licenses held by Amgen and Astellas are subject to Cytokinetics' specified co-development and co-commercialization rights. For additional information about Cytokinetics, visit http://www.cytokinetics.com/.

 

 

Semtech Demonstrates New 53GBaud PAM4 Linear Driver and Transimpedance Amplifier at OFC 2017

LOS ANGELES, CA...March 20, 2017 - Semtech Corporation (Nasdaq:SMTC), a leading supplier of analog and mixed-signal semiconductors, today announced a new 53GBaud PAM4 linear driver and transimpedance amplifier for 100G and 400G optical networking modules at OFC 2017. Semtech will privately demonstrate the new chipset in its OFC booth (#2575) at the Los Angeles Convention Center March 21-23.

The new 53GBaud PAM4 linear driver and transimpedance amplifier chipset supports the rapid adoption of 100G optical networking modules by hyperscale and cloud data center customers that are upgrading capacity and throughput. These high-bandwidth linear products reduce required optical components compared to NRZ or 26GBaud PAM4-based solutions, enabling lower cost modules and a streamlined roadmap to 400G (4x100G) optical networking applications.

"53GBaud PAM4 technology provides the optimal path to both 100G and 400G by creating a cost-efficient, integrated solution for customers," said Imran Sherazi of Marketing and Applications for Semtech's Signal Integrity Products Group. "The integrated solution provides a seamless interface to PAM4 optics and is tailored to next-generation 100G modules expected to pave the way to 400G."

The GN1189 is a high-bandwidth 53GBaud linear modulator driver, and the GN1089 is a high-performance, low-noise linear 53GBaud transimpedance amplifier. The OFC demonstration also includes a Receiver Optical Sub-Assembly (ROSA).

 

 

Semtech Announces Integrated Chipset for Next-Generation 100G QSFP28 Modules

LOS ANGELES, CA...March 20, 2017 - Semtech Corporation (Nasdaq:SMTC), a leading supplier of analog and mixed-signal semiconductors, today announced the initial production release of a highly integrated chipset for next-generation 100G QSFP28 modules used in data communications applications. Semtech will privately demonstrate the new chipset in its OFC booth (#2575) at the Los Angeles Convention Center March 21-23.

The new chipset includes GN2105, a quad ClearEdge™ CDR with an integrated DML driver for DC-coupled chip-on-board and passive transmitter optical sub-assembly applications, and GN2110, a quad ClearEdge CDR with integrated transimpedance amplifier (TIA) in a compact 3.6mm x 4mm die for chip-on-board applications.

"This innovative chipset enables next-generation, 100G QSFP28 designs that are used in high-speed data communications infrastructure to support some of the world's most dense and power-efficient communications networks," said Dr. Timothy Vang, Senior Director of Marketing for Semtech's Signal Integrity Products Group. "Semtech's optical networking products enable a lower cost structure while maintaining optimal signal integrity."

The highly integrated chipset is specifically tailored to customers' needs and provides overall cost savings for high-performance, low-power modules. Semtech's optical networking product portfolio includes integrated chipsets for reduced cost and robust feature sets that maintain signal integrity while supporting scalable data rates for a broad range of applications.

About Semtech's Optical Products
Semtech's optical networking products provide high-performance signal integrity for optical module solutions used by leading companies in the data center/enterprise networking, wireless infrastructure, and passive optical network/Fiber to the X markets. For more information, visit www.semtech.com/optical.

 

 

Semtech Launches New ClearEdge™ CDR for 100G QSFP28 Modules at OFC 2017

LOS ANGELES, CA...March 20, 2017 - Semtech Corporation (Nasdaq:SMTC), a leading supplier of analog and mixed-signal semiconductors, today announced the expansion of its ClearEdge™ CDR portfolio with a new ultra-low power, high-performance quad CDR for use in 100G QSFP28 modules. Semtech will privately demonstrate the new product in its OFC booth (#2575) at the Los Angeles Convention Center March 21-23.

The new ClearEdge CDR (GN2104S) enables low power (<3.5W) QSFP28 modules operating at 24G to 28G. These modules are used in 100G datacenter, enterprise and wireless applications.

"Semtech's low power, compact CDRs based on our proprietary ClearEdge Technology, deliver to our customers the differentiated features needed to support expansive 100G data center applications," said Gary Beauchamp, Executive Vice President and General Manager of Semtech's Signal Integrity Products Group. "Our market-leading CDRs feature excellent receiver sensitivity and best-in-class output jitter and jitter tolerance."

Key Features of the GN2104S

Semtech's new ClearEdge CDR consumes only 340mW total power, is offered in a very compact 3.5mm x 5.5mm CSP package, and achieves less than 5ps of total output jitter performance.

About Semtech's Optical Products

Semtech's optical networking products provide high-performance signal integrity for optical module solutions used by leading companies in the data center/enterprise networking, wireless infrastructure, and passive optical network/Fiber to the X markets. For more information, visit www.semtech.com/optical.

About OFC
The Optical Fiber Conference and Exposition (OFC) is the largest global conference and exhibition for optical communications and networking professionals. For more than 40 years, OFC has drawn attendees from all corners of the globe to meet and greet, teach and learn, make connections and move business forward.

OFC includes dynamic business programming, an exhibition of more than 600 companies, and high impact peer-reviewed research that, combined, showcase the trends and pulse of the entire optical networking and communications industry. OFC is managed by The Optical Society (OSA) and co-sponsored by OSA, the IEEE Communications Society (IEEE/ComSoc), and the IEEE Photonics Society. OFC 2017 will be held from 19-23 March 2017 at the Los Angeles Convention Center, California, USA. Follow @OFCConference, learn more OFC Conference LinkedIn and watch highlights OFC YouTube.

 

 

Repeat Oil and Gas Customer to Receive First Capstone C600 Signature Series Three Bay Package Microturbine

CHATSWORTH, CA...March 20, 2017 - Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq:CPST), the world's leading clean technology manufacturer of microturbine energy systems, announced today that it secured an order for a C600 Signature Series microturbine to power a natural gas compression station in southern Wyoming. This is the first order for a three bay package C600S microturbine, which has a smaller footprint and is lighter than the previous five bay package.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0e8cef91-4f4f-4521-afa0-b3db1660c8c1

Horizon Power Systems, Capstone's oil and gas distributor for the Eagle Ford, Permian, Barnett, Mancos, San Juan, and Wattenberg Shale plays, secured the order, which is expected to ship in the next few weeks and be commissioned in September 2017. This customer continues to buy Capstone microturbines for their low maintenance and ability to provide reliable power in remote locations.

"The oil, gas and other natural resources market continues to be an important market vertical for Capstone as we strive to improve our vertical market diversification with a goal of 40% oil, gas and other natural resources, 40% energy efficiency and 20% renewable energy and critical power applications," said Darren Jamison, Capstone's President and Chief Executive Officer. "Last quarter oil, gas and other natural resources comprised 38% of revenue with energy efficiency coming in at 53% and renewable energy and critical power representing 9%," added Mr. Jamison.

The dual mode C600S microturbine will be fueled by natural gas from a nearby pipeline and provide primary power to the compression station. Although Capstone has smaller units running statewide, the larger 600kW microturbine will be the first to be installed in the state of Wyoming.

According to the U.S. Energy Information Administration (EIA), Wyoming supplies more energy to other states and has more federal oil and natural gas leases than any other state. Wyoming produced 6.2 percent of the nation's marketed natural gas in 2015, and continues to stand as one of the top 10 natural gas producing states in the United States.

"We are seeing a steady increase in our global oil and gas business," said Jim Crouse, Capstone's Executive Vice President of Sales and Marketing. "Repeat oil and gas customers like this help to solidify Capstone's position as the microturbine market leader and the preferred go-to power solution in the recovering oil and gas market. The new three bay enclosure is a nice new benefit as customers across all our market verticals enjoy smaller and lighter packages that are less costly to ship and easier to install," added Mr. Crouse.

 

 

Corium Reports Positive Progress in Pilot Bioequivalence Study of Once-Weekly Corplex™ Donepezil Patch

MENLO PARK, CA...March 20, 2017 - Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today reported on positive progress in the pilot bioequivalence (BE) study of its Corplex Donepezil candidate, a once-weekly transdermal patch for delivery of the most commonly prescribed treatment for the symptoms of Alzheimer's disease.

The pilot BE study is a three-period, randomized crossover study comparing the steady-state pharmacokinetic (PK) profiles of once-daily oral Aricept® (donepezil hydrochloride) with two Corplex Donepezil transdermal patches that differ only in surface area. Corium reported that the steady-state PK profiles of the transdermal dosage forms measured in the second treatment period, which includes partial crossover data, continue to exhibit a close similarity with the oral PK results and were indicative of bioequivalence. The Corplex transdermal systems continued to be well tolerated, with favorable skin safety and gastrointestinal side effect profiles.

The company reported that the pilot study is on track for completion of the third and final treatment period in April and expects to report on results from the entire study in May.

The objective of the pilot study is to enable the company to finalize key parameters, including patch surface area and number of subjects, for a successful pivotal BE study. The primary objective of the pivotal study will be the demonstration of statistically similar PK profiles between the final transdermal candidate and the oral dosage form. Corium is pursuing the BE development and regulatory pathway based on written feedback provided by the FDA in 2016.

"We are very encouraged with the positive progress in the crossover clinical study of our lead Alzheimer's program and the continued low attrition rates," said Peter D. Staple, President and Chief Executive Officer of Corium. "With our extensive experience in successfully conducting pilot and pivotal bioequivalence studies, we are well-positioned for the upcoming pivotal BE study. Preparations for the pivotal study, expected to commence later in 2017, are well underway, and we look forward to advancing this candidate towards an NDA filing in 2018. We believe Corplex Donepezil will provide an important new treatment option to improve the lives of Alzheimer's patients and their caregivers."

About Alzheimer's Disease and Donepezil

Alzheimer's disease is a progressive brain disorder in which the brain cells degenerate and die, causing a steady decline in memory and mental function. An estimated 5.5 million Americans are living with Alzheimer's disease in 2017; by 2025, this number is expected to exceed 7 million. Alzheimer's disease is the most common cause of dementia among older adults. Dementia ranges in severity from mild, when it is just beginning to affect a person's functioning, to moderate, and severe, when the person must depend on others for the basic activities of day-to-day life.

Donepezil (the active ingredient in Aricept) is the most widely prescribed medication in a class of Alzheimer's drugs known as cholinesterase inhibitors, and is approved for the treatment of mild, moderate and severe disease. Donepezil is currently only available in tablet or orally disintegrating tablet form, each administered once daily, presenting compliance challenges for family members and caregivers who cannot rely on patients to consistently take their daily tablets, and is known to cause gastrointestinal side effects, including nausea, vomiting and loss of appetite.

About Corplex

Corium's Corplex system is a novel commercial-stage platform technology designed to broadly enable the transdermal delivery of small molecules, many of which have not previously been amenable to transdermal delivery. Corplex advanced transdermal and transmucosal systems are broadly adaptable for use in multiple drug categories and indications, and have the potential to reduce quantities of active ingredient utilized in transdermal products. Additionally, Corplex transdermal patches can enable efficient drug delivery, and adhere to either wet or dry surfaces for an extended period of time. Corium's Corplex technology has been successfully commercialized in Procter & Gamble's Crest® Whitestrips products, and is being utilized in several proprietary therapeutic products under development.

About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumgroup.com.

 

 

Watch Winning the Online Game Presentation Live From Vision Expo East

SAN DIEGO, CA...March 20, 2017 - The educational presentation, Winning the Online Game – Any Practice Can Be #1 Online, will be presented via live-stream from International Vision Expo East, one of the vision industry's largest product and learning conferences. Featuring speaker Chad Fleming, OD, FAAO, and presented by iMatrix, the leader in online marketing solutions for eye care professionals, the one-hour course will give hope to eye care practices who are not seeing new patient growth from online efforts and need help in extending their physical practice to the online community.

The live-stream event will happen Friday, March 31, at 11 a.m. ET (8 a.m. PT). Register for free access online at: http://go.imatrix.com/l/188012/2017-03-14/553v2

Fleming is a partner and business manager of Wichita Optometry – a busy two-location practice with five optometrists serving west Wichita, Kan. As the manager of his practice's online presence, he will discuss his successful online strategy with real life experiences and teach easy and practical methods for how eye care practices can get more business online. Topics he will cover include: how to resonate with Millennials, cater to mobile only-users and uphold patient's online expectations.

In-person expo attendees will also be able to connect with Fleming for further marketing help at the iMatrix booth in the exhibitor's hall where they will also be able to receive a free website evaluation from one of iMatrix's online marketing experts.

International Vision Expos, is a biannual worldwide conference and exhibition for eye care and eyewear, are trade-only events that draw more than 30,000 eye care professionals each year. The spring east coast expo is taking place at the Javits Center in New York, NY, March 30 through April 2. The west coast expo will be held this fall in Las Vegas.

About iMatrix

Founded in 2002 and currently serving more than 12,000 clients, iMatrix is a leading provider of website services and internet marketing solutions for eye care providers. The company provides small, practice-based businesses with online marketing solutions for every need and within every budget. From mobile-friendly website design to advanced search engine optimization and custom content, iMatrix offers a wide range of digital marketing tools and services to help its client's succeed online. Based in San Diego, iMatrix is also a Premier Google Partner. Learn more at www.iMatrix.com

 

 

Aerojet Rocketdyne Supports ULA Launch of Wideband Global SATCOM Spacecraft for the U.S. Military

SACRAMENTO, CA...March 20, 2017 - Aerojet Rocketdyne, Inc., a subsidiary of Aerojet Rocketdyne Holdings, Inc. (NYSE:AJRD), played a major role in successfully launching and placing the ninth Wideband Global SATCOM (WGS-9) spacecraft into orbit for the U.S. military. The mission was launched from Cape Canaveral Air Force Station in Florida aboard a United Launch Alliance (ULA) Delta IV rocket. Aerojet Rocketdyne propulsion systems included the RS-68A booster engine, the RL10B-2 upper-stage engine, 14 helium pressurization tanks, and a 100 lbf bipropellant apogee-raising engine aboard the WGS-9 spacecraft.

"The WGS satellites provide critical communication capabilities for our nation's warfighters," said Aerojet Rocketdyne CEO and President Eileen Drake. "We are honored that our propulsion systems are called upon to place these critical payloads into orbit – payloads that will help protect our nation and allied forces."

Aerojet Rocketdyne's role in the launch began when a single RS-68A engine ignited to boost the Delta IV off the pad, providing 702,000 pounds of lift-off thrust. The RS-68A is the world's most powerful liquid hydrogen/liquid oxygen engine. The RS-68 family of engines has now flown 35 commercial and government missions with 100 percent mission success.

After the upper stage separated from the launch vehicle, a single RL10B-2 upper-stage engine ignited to place the payload into orbit. The RL10B-2 delivers 24,750 pounds of thrust to power the Delta IV upper stage, using cryogenic liquid hydrogen and liquid oxygen propellants.

The RL10B-2 was developed from the RL10 family of upper-stage engines, which has accumulated one of the most impressive track records of accomplishments in the history of space propulsion. More than 475 RL10 engines have supported launches over the last 50 years, playing a vital role in placing military, government and commercial satellites into orbit, and powering scientific space probes on every interplanetary mission in our solar system. ARDÉ, a subsidiary of Aerojet Rocketdyne based in New Jersey, manufactures the pressure vessels on the first and second stages of the launch vehicle.

Once separated from the launch vehicle, WGS-9 will perform multiple burns on Aerojet Rocketdyne's High Performance Apogee Thruster (HiPAT™) rocket engine to complete the orbit raising from Geosynchronous Transfer Orbit to its final geosynchronous orbital position. The HiPAT™ rocket engine has a 100 percent mission success track record spanning over 115 missions, including all WGS spacecraft.

The Boeing-built WGS satellites provide increased military communications capabilities for U.S. and allied forces deployed worldwide. They help support the exchange of information, execution of tactical command and control, intelligence, surveillance and reconnaissance.

Aerojet Rocketdyne is an innovative company delivering solutions that create value for its customers in the aerospace and defense markets. The company is a world-recognized aerospace and defense leader that provides propulsion and energetics to the space, missile defense and strategic systems, tactical systems and armaments areas, in support of domestic and international markets. Additional information about Aerojet Rocketdyne can be obtained by visiting our websites at www.Rocket.com and www.AerojetRocketdyne.com.